Physician profile
Meyer S Halberstam
NPI 1225026511
$142,694.54
in general payments reported to CMS, 2019-2025
37 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $35K · 2021: $25K · 2022: $8,836 · 2023: $35K · 2024: $279 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $1,395 · Travel and Lodging: $47.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,975.00 |
| Food and Beverage | $1,394.94 |
| Travel and Lodging | $47.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $58,771.96 | 2019-2025 | Jardiance, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45,085.49 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $31,352.83 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $3,885.58 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $717.84 | 2019-2021 | |
| Genzyme Corporation | $592.00 | 2019-2020 | |
| Amgen INC. | $430.71 | 2019-2025 | Tepezza, Repatha, Otezla |
| Sanofi US Services INC. | $325.00 | 2021 | |
| Insulet Corporation | $223.52 | 2023-2025 | Omnipod |
| Dexcom, INC. | $160.00 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Xeris Pharmaceuticals, INC. | $130.21 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Amneal Pharmaceuticals LLC | $111.97 | 2022-2023 | Unithroid |
| Corcept Therapeutics | $101.24 | 2024-2025 | Korlym |
| Novo Nordisk INC | $96.52 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $66.48 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $55.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.24 | 2023-2025 | Vpriv |
| Abbvie INC. | $50.27 | 2021 | |
| Grt US Holding, INC. | $50.14 | 2021-2022 | |
| Renalytix Ai, INC. | $48.54 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Amarin Pharma, INC. | $41.47 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.63 | 2019 | |
| Ionis Pharmaceuticals, INC. | $32.66 | 2025 | Tryngolza |
| Paratek Pharmaceuticals, INC. | $32.63 | 2023 | Nuzyra |
| Gilead Sciences, INC. | $29.38 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.93 | 2019 | |
| Nevro Corp. | $23.87 | 2021 | |
| Allergan, INC. | $20.00 | 2019 | |
| Medtronic Minimed, INC. | $19.04 | 2020 | |
| Medtronic, INC. | $18.96 | 2022 | |
| Radius Health, INC. | $16.54 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.53 | 2021 | |
| Antares Pharma, INC. | $16.49 | 2023 | Nocdurna, Tlando, Xyosted |
| Almatica Pharma LLC | $16.24 | 2021 | |
| Pfizer INC. | $15.56 | 2019 | |
| Sanofi Pasteur INC. | $14.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meyer Halberstam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.